Impact of Immunohistochemical Biomarkers on Predicting the Risk of Biochemical Recurrence for Patients that Underwent Radical Prostatectomy: A Literature Review

Mihnea Bogdan Borz ¹, Vlad Horia Schitcu ¹, Bogdan Fetica ²

⁰Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

Archivos Espanoles De Urologia +

|

September 6, 2024

View abstract on PubMed

Summary

Biomarkers like LIMK1, Ki67, PTEN, and ERG show promise in predicting prostate cancer recurrence after surgery. Integrating these markers can personalize patient follow-up and treatment strategies.

Area Of Science

Oncology
Biomarker Research
Molecular Pathology

Background

Prostate cancer (PCa) is a major global health concern with variable clinical behaviors.
Accurate assessment of PCa aggressiveness and personalized treatment remain challenging.
Biomarkers are vital for risk stratification, treatment selection, and prognosis in PCa management.

Purpose Of The Study

To evaluate the clinical significance of specific biomarkers in predicting biochemical recurrence (BCR) after radical prostatectomy.
To assess the role of LIM domain kinase 1 (LIMK1), Ki67, PTEN, and ERG in PCa management.
To explore the potential for personalized follow-up and intervention in high-risk PCa patients.

Main Methods

A comprehensive literature review of articles published between 2019 and 2024.
Focused search on the correlation between LIMK1, Ki67, PTEN/ERG biomarkers and BCR.
Inclusion of 36 articles after applying exclusion criteria.

Main Results

LIMK1 expression correlates with poor prognosis, aggressive PCa, and BCR.
Ki67, a proliferation marker, predicts high-risk PCa and worse prognosis, though its recurrence association is debated.
PTEN loss is linked to poor prognosis, and ERG fusion is associated with increased disease progression and BCR.

Conclusions

Integrating LIMK1, Ki67, PTEN, and ERG biomarkers can improve risk stratification for PCa patients.
These biomarkers hold potential for informing personalized treatment and follow-up strategies.
Further validation and standardization are necessary to optimize their clinical utility for improved patient outcomes.

Keywords:

ERG Ki67 LIMK1 PTEN prostate cancer